Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 30

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double‐blind, randomized controlled VaSera trial

Faconti, Luca, Mills, Charlotte Elizabeth, Govoni, Virginia, Gu, Haotian, Morant, Steven, Jiang, Benju, Cruickshank, J. Kennedy, Webb, Andrew James · 2019 · British Journal of Clinical Pharmacology

Abstract

Aims: The aims of the present study were to explore whether a long‐term intervention with dietary nitrate [(NO 3−), a potential tolerance‐free source of beneficial vasoactive nitric oxide] and spironolactone (to oppose aldosterone's potential deleterious cardiovascular effects) improve cardiac structure/function, independently of blood pressure (BP), in patients with/at risk of type 2 diabetes (a population at risk of heart failure). Methods: A subsample of participants in our double‐blind, randomized, factorial‐design intervention (VaSera) trial of active beetroot juice as a nitrate source (≤11.2 mmol) or placebo (nitrate depleted) beetroot juice, and either ≤50 mg spironolactone or ≤16 mg doxazosin (control), had transthoracic cardiac ultrasounds at baseline (n = 105), and at 3 months and 6 months (n = 87) after the start of the intervention. Analysis was by modified intent‐to‐treat. Results: Nitrate‐containing juice (n = 40) decreased left ventricular (LV) end‐diastolic volume {−6.3 [95% confidence interval (CI) –11.1, –1.6] ml} and end‐systolic volume [−3.2 (95% CI −5.9, –0.5) ml], and increased end‐diastolic mass/volume ratio [+0.04 (95% CI 0.00, 0.07)], relative to placebo juice (n = 47). Spironolactone (n = 44) reduced relative wall thickness compared with doxazosin (n = 43) [−0.01 (95% CI −0.02, –0.00)]. Although spironolactone reduced LV mass index relative to baseline [−1.48 (95% CI −2.08, –0.88) g m–2.7], there was no difference vs. doxazosin [−0.85 (95% CI −1.76, 0.05) g m–2.7]. Spironolactone also decreased the E/A ratio [−0.12 (95% CI −0.19, –0.04)] and increased S′ (a tissue‐Doppler systolic function index) by 0.52 (95% CI 0.05, 1.0) cm s–1. BP did not differ between the juices, or between the drugs. Conclusions: Six months' dietary nitrate decreased LV volumes ~5%, representing new, sustained, BP‐independent benefits on cardiac structure, extending mechanisms characterized in preclinical models of heart failure. Spironolactone's effects on cardiac remodelling and systolic–diastolic function, although confirmatory, were independent of BP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bcp.13783

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 45

  1. 10.1186/1475-2840-8-15 · DOI
  2. 10.1016/j.numecd.2008.12.009 · DOI
  3. 10.1093/nar/gkx1121 · DOI · Paper page
  4. 10.1111/bph.13354 · DOI · Paper page
  5. Jin RC, 2010, Vascular nitric oxide: formation and function, J Blood Med, 2010, 147
  6. 10.1111/j.1463-1326.2007.00803.x · DOI
  7. 10.1016/j.amjcard.2016.08.077 · DOI
  8. 10.1056/NEJMoa1510774 · DOI · Paper page
  9. Webb A, 2010, Nitric Oxide (Second Edition). Biology and Pathobiology, 555
  10. 10.3945/ajcn.115.116244 · DOI · Paper page
  11. 10.1111/bcp.12913 · DOI
  12. 10.1161/HYPERTENSIONAHA.107.103523 · DOI · Paper page
  13. 10.1016/j.niox.2017.05.005 · DOI
  14. 10.1016/j.jacc.2017.07.765 · DOI
  15. 10.1111/bcp.12918 · DOI
  16. 10.1161/CIRCULATIONAHA.114.009554 · DOI
  17. 10.1016/j.jacc.2017.10.093 · DOI
  18. 10.1161/CIRCRESAHA.116.305082 · DOI
  19. 10.1093/eurheartj/ehu096 · DOI
  20. 10.1111/bcp.13231 · DOI
  21. 10.1161/CIRCRESAHA.114.303822 · DOI · Paper page
  22. 10.1161/JAHA.116.003551 · DOI
  23. 10.1161/01.CIR.92.2.175 · DOI · Paper page
  24. 10.1111/bph.13352 · DOI · Paper page
  25. 10.1016/j.jacc.2009.03.066 · DOI · Paper page
  26. 10.1016/j.artres.2015.10.194 · DOI
  27. 10.1111/bph.13348 · DOI · Paper page
  28. 10.1016/j.echo.2014.10.003 · DOI · Paper page
  29. 10.1016/j.echo.2016.01.011 · DOI · Paper page
  30. 10.1111/bcp.13254 · DOI
  31. 10.1016/j.jacc.2015.07.067 · DOI · Paper page
  32. 10.1016/j.jacc.2017.05.029 · DOI · Paper page
  33. 10.1161/CIRCULATIONAHA.107.719591 · DOI · Paper page
  34. 10.1016/0002-9149(87)90362-6 · DOI
  35. 10.1016/j.jacc.2011.09.062 · DOI · Paper page
  36. 10.1016/j.hfc.2007.10.001 · DOI · Paper page
  37. 10.1161/CIRCIMAGING.109.911438 · DOI
  38. 10.1161/CIRCIMAGING.109.883652 · DOI · Paper page
  39. 10.1016/j.jash.2017.05.005 · DOI
  40. 10.1291/hypres.25.837 · DOI
  41. 10.1093/ehjci/jeu013 · DOI
  42. 10.1161/01.HYP.0000121223.44837.de · DOI · Paper page
  43. 10.1016/j.jacc.2007.03.062 · DOI
  44. 10.1001/jama.2013.905 · DOI · Paper page
  45. 10.1136/heartjnl-2012-303329 · DOI · Paper page

Cited by

See all 30

Metadata

Authors
Faconti, L., Mills, C. E., Govoni, V., Gu, H., Morant, S., Jiang, B., Cruickshank, J. K., & Webb, A. J.
Affiliations
  • Department of Clinical Pharmacology School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre London UK
  • Department of Nutritional Sciences, School of Life Course Sciences King's College London London UK
  • Medicines Monitoring Unit (MEMO) University of Dundee Dundee UK
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2018-11-13
Volume
85
Issue
1
Pages
169-180
ISSN
  • 0306-5251
  • 1365-2125
Cited by
30
References
11
Language
en
Funders
  • Fukuda Denshi Ltd
  • NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double‐blind, randomized controlled VaSera trial. https://app.cochat.ai/papers/10.1111/bcp.13783
The paper
Faconti, L., Mills, C. E., Govoni, V., Gu, H., Morant, S., Jiang, B., Cruickshank, J. K., & Webb, A. J. (2019). Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double‐blind, randomized controlled VaSera trial. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.13783

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.